The U.S. Supreme Court will hear Bayer’s (BAYRY) appeal challenging thousands of lawsuits that claim its top-selling Roundup weed killer causes cancer, Bloomberg’s Jef Feeley reports. The high court agree to hear the company’s appeal of a $1.25M Missouri jury verdict over the product on the grounds that some of the claims in the 2023 case were preempted by federal law, the author says, noting that Bayer officials hope the court’s ruling will help block thousands of Roundup cases that include failure-to-warn claims.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis
- Bayer’s FINE-REAL Korea Study Tracks Real-World Use of Finerenone in Diabetic Kidney Disease
- Bayer’s New Parkinson’s Study Builds a Long-Term Data Edge, Not Near-Term Profits
- Bayer, Souffle Therapeutics report global licensing agreement for siRNA therapy